Tags

Type your tag names separated by a space and hit enter

Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
Nephron Clin Pract. 2005; 99(3):c78-85.NC

Abstract

BACKGROUND

Useful markers of bone resorption are needed for hemodialysis patients with renal osteodystrophy. This study investigated the use of a new immunoassay for cross-linked N-terminal telopeptide of type 1 collagen to assess bone changes in hemodialysis patients.

METHODS

Radial bone mineral density was examined in 178 hemodialysis patients at baseline and after 12 months. Serum levels of N-terminal telopeptide and other markers were measured.

RESULTS

The annual percent change of radial bone mineral density was negatively correlated with the levels of N-terminal telopeptide, intact osteocalcin, tartrate-resistant acid phosphatase, bone-specific alkaline phosphatase, and intact parathyroid hormone. The annual percent change of radial bone mineral density showed a stronger correlation with N-terminal telopeptide levels than with the other markers, except for intact parathyroid hormone. Also, intact parathyroid hormone and N-terminal telopeptide levels showed a stronger correlation than that of either tartrate-resistant acid phosphatase or cross-linked carboxyterminal telopeptide of type 1 collagen with intact parathyroid hormone.

CONCLUSION

Serum N-terminal telopeptide may be the most useful bone resorption marker in renal osteodystrophy and its use combined with bone formation markers may improve the management of this condition.

Authors+Show Affiliations

Department of Internal Medicine, Hakuai Hospital, Kure, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15665550

Citation

Nakashima, Ayumu, et al. "Serum Cross-linked N-terminal Telopeptide of Type I Collagen for Evaluation of Renal Osteodystrophy in Hemodialysis Patients." Nephron. Clinical Practice, vol. 99, no. 3, 2005, pp. c78-85.
Nakashima A, Yorioka N, Mizutani T, et al. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. Nephron Clin Pract. 2005;99(3):c78-85.
Nakashima, A., Yorioka, N., Mizutani, T., Yamagata, Z., Ueno, T., & Takasugi, N. (2005). Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. Nephron. Clinical Practice, 99(3), c78-85.
Nakashima A, et al. Serum Cross-linked N-terminal Telopeptide of Type I Collagen for Evaluation of Renal Osteodystrophy in Hemodialysis Patients. Nephron Clin Pract. 2005;99(3):c78-85. PubMed PMID: 15665550.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. AU - Nakashima,Ayumu, AU - Yorioka,Noriaki, AU - Mizutani,Takashi, AU - Yamagata,Zentaro, AU - Ueno,Toshinori, AU - Takasugi,Norihisa, Y1 - 2005/01/19/ PY - 2004/07/14/received PY - 2004/08/06/accepted PY - 2005/1/25/pubmed PY - 2006/4/7/medline PY - 2005/1/25/entrez SP - c78 EP - 85 JF - Nephron. Clinical practice JO - Nephron Clin Pract VL - 99 IS - 3 N2 - BACKGROUND: Useful markers of bone resorption are needed for hemodialysis patients with renal osteodystrophy. This study investigated the use of a new immunoassay for cross-linked N-terminal telopeptide of type 1 collagen to assess bone changes in hemodialysis patients. METHODS: Radial bone mineral density was examined in 178 hemodialysis patients at baseline and after 12 months. Serum levels of N-terminal telopeptide and other markers were measured. RESULTS: The annual percent change of radial bone mineral density was negatively correlated with the levels of N-terminal telopeptide, intact osteocalcin, tartrate-resistant acid phosphatase, bone-specific alkaline phosphatase, and intact parathyroid hormone. The annual percent change of radial bone mineral density showed a stronger correlation with N-terminal telopeptide levels than with the other markers, except for intact parathyroid hormone. Also, intact parathyroid hormone and N-terminal telopeptide levels showed a stronger correlation than that of either tartrate-resistant acid phosphatase or cross-linked carboxyterminal telopeptide of type 1 collagen with intact parathyroid hormone. CONCLUSION: Serum N-terminal telopeptide may be the most useful bone resorption marker in renal osteodystrophy and its use combined with bone formation markers may improve the management of this condition. SN - 1660-2110 UR - https://www.unboundmedicine.com/medline/citation/15665550/Serum_cross_linked_N_terminal_telopeptide_of_type_I_collagen_for_evaluation_of_renal_osteodystrophy_in_hemodialysis_patients_ L2 - https://www.karger.com?DOI=10.1159/000083418 DB - PRIME DP - Unbound Medicine ER -